Where Will Regulus Therapeutics Inc (RGLS) Stock Go Next After It Has Fallen 10.20% in a Week?

Overall market sentiment has been down on Regulus Therapeutics Inc (RGLS) stock lately. RGLS receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Regulus Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RGLS!

See Full RGLS Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With RGLS Stock Today?

Regulus Therapeutics Inc (RGLS) stock is trading at $0.44 as of 10:56 AM on Friday, Oct 22, a decline of -$0.03, or -6.33% from the previous closing price of $0.47. The stock has traded between $0.44 and $0.47 so far today. Volume today is 1,853,984 compared to average volume of 2,237,574.

More About Regulus Therapeutics Inc

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes. Click Here to get the full Stock Report for Regulus Therapeutics Inc stock.